Serum alpha-fetoprotein measurement in predicting clinical outcome related to autologous cytokine-induced killer cells in patients with hepatocellular carcinoma undergone minimally invasive therapy

Chinese Journal of Cancer

Volumn 29, Issue 6, 2010, Pages 596-602

  Pan, Chang Chuan ^a   Huang, Zi Lin ^a   Li, Wang ^a   Zhao, Ming ^a   Zhou, Qi Ming ^a   Xia, Jian Chuan ^a   Wu, Pei Hong ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Alpha fetoprotein; Cytokine induced killer cells; Liver neoplasm

Indexed keywords

ALPHA FETOPROTEIN; CISPLATIN; IODINATED POPPYSEED OIL; MITOMYCIN; PIRARUBICIN; VIRUS DNA;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHEMOEMBOLIZATION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CYTOKINE INDUCED KILLER CELL; FEMALE; FLOW CYTOMETRY; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PROTEIN BLOOD LEVEL; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE; TOMOGRAPHY; TUMOR RECURRENCE;

EID: 79955863760     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.009.10580     Document Type: Article

References (27)

1. Livraghi T, Meloni F, Di Stasi M, et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice? [J]. Hepatology, 2008, 47(1): 82-89.
2. Zhou QM, Wu PH, Zhao M, et al. Short-term curative efficacy of cytokine-induced killer cells combined microinvasive treatments on hepatocellular carcinoma [J]. Chin J Cancer, 2006, 25(11): 1414-1418. [in Chinese]
3. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008 [J]. J Hepatol, 2008, 48 Suppl (1): S20-37.
4. Nakamoto Y, Guidotti LG, Kuhlen CV, et al. Immune pathogenesis of hepatocellular carcinoma [J]. J Exp Med, 1998, 188(2): 341-350.
5. Kojiro M, Nakashima O. Histopathologic evaluation of hepatocellular carcinoma with special reference to small early stage tumors [J]. Semin Liver Dis, 1999(3), 19: 287-296.
6. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development [J]. Nat Rev Cancer, 2006, 6(1): 24-37.
7. Cucchetti A, Piscaglia F, Caturelli E, et al. Comparison of recurrence of hepatocellular carcinoma after resection in patients with cirrhosis to its occurrence in a surveilled cirrhotic population [J]. Ann Surg Oncol, 2009, 16(2): 413-422.
8. Takayama T, Sekine T, Makuuchi M, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomized trial [J]. Lancet, 2000, 356(9232): 802-807.
9. Weng DS, Zhou J, Zhou QM, et al. Minimally invasive treatment combined with cytokine-induced killer cells therapy lower the short-term recurrence rates of hepatocellular carcinomas [J]. J Immunother, 2008, 31(1): 63-71.
10. Xu X, Ke QH, Shao ZX, et al. The value of serum alpha-fetoprotein in predicting tumor recurrence after liver transplantation for hepatocellular carcinoma [J]. Dig Dis Sci, 2009, 54(2): 385-388.
11. Vora SR, Zheng H, Stadler ZK, et al. Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma [J]. Oncologist, 2009, 14(7): 717-725.
12. Chan SL, Mo FK, Johnson PJ, et al. New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy [J]. J Clin Oncol, 2009, 27(3): 446-452.
13. Bruix J, Sherman M. Management of hepatocellular carcinoma [J]. Hepatology, 2005, 42(5): 1208-1236.
14. Ruoslahti E, Seppala M. Studies of carcino-fetal proteins. 3. Development of a radioimmunoassay for-fetoprotein. Demonstration of-fetoprotein in serum of healthy human adults [J]. Int J Cancer, 1971, 8(3): 374-383.
15. Han SJ, Yoo S, Choi SH, et al. Actual half-life of alpha-fetoprotein as a prognostic tool in pediatric malignant tumors [J]. Pediatr Surg Int, 1997, 12(8): 599-602.
16. Cedrone A, Covino M, Caturelli E, et al. Utility of alpha-fetoprotein (AFP) in the screening of patients with virus-related chronic liver disease: does different viral etiology influence AFP levels in HCC? A study in 350 western patients [J]. Hepatogastroenterology, 2000, 47(36): 1654-1658.
17. Soresi M, Magliarisi C, Campagna P, et al. Usefulness of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma [J]. Anticancer Res, 2003, 23(2): 1747-1753.
18. Johnson PJ. The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma [J]. Clin Liver Dis, 2001, 5(1): 145-159.
19. Collier J, Sherman M. Screening for hepatocellular carcinoma [J]. Hepatology, 1998, 27(1): 273-278.
20. Mizejewski GJ. Alpha-fetoprotein structure and function: relevance to isoforms, epitopes, and conformational variants [J]. Exp Biol Med (Maywood), 2001, 226(5): 377-408.
21. Evdokimova VN, Liu Y, Potter DM, et al. AFP-specific CD4+ helper T-cell responses in healthy donors and HCC patients [J]. J Immunother, 2007, 30(4): 425-437.
22. Parmiani G, Anichini A. T cell infiltration and prognosis in HCC patients [J]. J Hepatol, 2006, 45(2): 178-181.
23. Dudich E, Semenkova L, Gorbatova E, et al. Growth-regulative activity of human alpha-fetoprotein for different types of tumor and normal cells [J]. Tumour Biol, 1998, 19(1): 30-40.
24. Li MS, Li PF, Yang FY, et al. The intracellular mechanism of alpha-fetoprotein promoting the proliferation of NIH 3T3 cells [J]. Cell Res, 2002, 12(2): 151-156.
25. Li MS, Ma QL, Chen Q, et al. Alpha-fetoprotein triggers hepatoma cells escaping from immune surveillance through altering the expression of Fas/FasL and tumor necrosis factor related apoptosis-inducing ligand and its receptor of lymphocytes and liver cancer cells [J]. World J Gastroenterol, 2005, 11(17): 2564-2569.
26. Nagao M, Nakajima Y, Kanehiro H, et al. The impact of interferon gamma receptor expression on the mechanism of escape from host immune surveillance in hepatocellular carcinoma [J]. Hepatology, 2000, 32(1): 491-500.
27. Shi M, Fu J, Shi F, et al. Transfusion of autologous cytokine-induced killer cells inhibits viral replication in patients with chronic hepatitis B virus infection [J]. Clin Immunol, 2009, 132(1): 43-54.